Navigation Links
Caliper Announces New Oncology Research Collaboration
Date:4/5/2011

HOPKINTON, Mass., April 5, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has formed a research collaboration with Denver-based Catholic Health Initiatives (CHI), one of the nation's largest health systems.

The health care system's Center for Translational Research (CTR), which is part of CHI's Institute for Research and Innovation, will work with Caliper to develop improved methods for evaluating and predicting the efficacy of new cancer drugs.  Under this program, CTR will provide fresh human tumor samples to CDAS for CDAS to perform biomarker and standard-of-care drug resistance/sensitivity studies on these samples.  CDAS will grow the CTR samples under various experimental conditions, including traditional two-dimensional cell culture, three-dimensional (3-D) in vitro culture, and in vivo culture in mice, and the CTR will supply key treatment history and diagnostic data for these tumor sources.

The drug discovery industry demands better, more clinically relevant drug screening services utilizing cellular models that mimic the function of living tissues to reduce the drug candidate attrition rate between the stages of in vitro and in vivo experimentation. Optimized 3D cell assays or assays performed on human tumor cells maintained in a similar tumor microenvironment under the skin of mice, may provide valuable information to better predict drug efficacy in humans. CDAS provides oncology drug discovery assays based on a variety of biological output parameters such as proliferation, viability, apoptosis or specific biomarkers applied under conventional monolayer cell culture conditions. This new collaboration allows these testing methods to be extended to fresh tumor cells mai
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
2. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
3. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
4. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
5. Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
6. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
7. Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line
8. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
9. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
10. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
11. Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... HILLS, Calif. , May 23, 2013  Saddleback ... recently became the first hospital on the ... robotic technology. This new surgical option provides women with ... Marc Winter , M.D., ... gynecologist and surgeon and medical director of minimally invasive ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... 23, 2013 Pusan National University Yangsan ... biotherapeutics and contract research company focused on research ... announced today a publication reporting the induction of ... oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex ... in the May 15 th , 2013 issue ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Ascenta Therapeutics announced today that promising results from ongoing ... the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at ... May 29-June 2, in Orlando, Florida. , , ... , , , "We are delighted with ...
... indicate target-dependent activity in breast cancer patients with high ... 1 Micromet, Inc. (Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune diseases, presented data ... adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in ...
... LLC, a box manufacturer, launches an online store offering cryogenic freezer ... ... Avon, OH (PRWEB) May 31, 2009 -- A box ... boxes online directly to labs at guaranteed low prices. Cryovial ...
Cached Biology Technology:Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 3Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 5Box maker, Wildcat Wholesale, Makes Cryogenic Freezer Storage Boxes Affordable By Selling Directly To Labs 2
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... A new report from the Institute of Medicine ... in at least 60 minutes of vigorous or moderate ... than half of American youth meet current evidence-based guidelines ... intensity physical activity daily, according to the report, which ... school for nearly half of their waking hours, the ...
(Date:5/23/2013)... , the team reveal the interplay of brain chemicals ... the Wellcome Trust and BBSRC. , By changing ... our perceptual abilities. While these changes can affect the ... the fidelity of that response. , Lead ... you communicate with others, you can make yourself better ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
... SomaLogic, Inc., announced today that it will receive ... Melinda Gates Foundation,s Grand Challenges in Global Health program, ... creating new tools that can radically improve health in ... Diseases Research Group at SomaLogic, will pursue an innovative ...
... The University of Nottingham has shown that babies who are ... healthier food preferences and are less likely to become overweight ... The research just published by BMJ Open set ... preferences and Body Mass Index in early childhood in a ...
... HOUSTON -- (Feb. 9, 2012) Aging takes its ... researchers led by Baylor College of Medicine and ... least, it even diminishes the come-hither effect of the chemicals ... we have direct evidence that the pheromones produced at these ...
Cached Biology News:SomaLogic Inc. receives Grand Challenges tuberculosis biomarkers grant 2Baby knows best! Study shows baby-led weaning promotes healthy food preferences 2Baby knows best! Study shows baby-led weaning promotes healthy food preferences 3Fruit flies drawn to the sweet smell of youth 2
...
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Synaptic Vesicle I Sampler Kit 10g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Biology Products: